Previous Article | Next Article 
Journal of Clinical Microbiology, July 1998, p. 1853-1858, Vol. 36, No. 7
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Characterization of Glycopeptide-Resistant
Enterococci from a Swiss Hospital
Nadia
Liassine,1,*
Reno
Frei,2
Isabelle
Jan,1 and
Raymond
Auckenthaler1
Central Laboratory of Bacteriology,
University Hospital, Geneva,1 and
Bacteriology Laboratory, University Clinics,
Basel,2 Switzerland
Received 30 October 1997/Returned for modification 30 December
1997/Accepted 17 March 1998
 |
ABSTRACT |
Between August 1994 and September 1996, 28 glycopeptide-resistant
enterococci (GRE) were isolated from 8 infected patients and 11 intestinal carriers hospitalized at the University Hospital of Geneva.
Identification to the species was made by both phenotypic (API 20 STREP
and Rapid ID 32 STREP systems, and Vitek Gram Positive Identification
Card) and genotypic methods using a multiplex PCR assay developed also
for the determination of the genotype of glycopeptide
resistance (vanA, vanB, vanC1, and
vanC2-C3 genes). Fifteen isolates were identified as
Enterococcus faecium, 8 as E. gallinarum, 4 as
E. faecalis, and 1 as E. hirae. All of the phenotypic identification methods failed to differentiate some isolates of E. gallinarum from E. faecium, or
vice versa. Both vanA (n = 18) and
vanB (n = 4) glycopeptide resistance
genotypes were found. For the first time, the vanB
determinant was found in two isolates of E. gallinarum. Two
patients were colonized by two different species containing the
vanA gene and one by two different species containing the
vanB gene. All vanA isolates were
highly resistant to both vancomycin and teicoplanin except for
three isolates which were susceptible to teicoplanin. Molecular typing
by pulsed-field gel electrophoresis showed identical or similar
patterns among E. faecium isolates with the
vanA gene in five patients for whom the epidemiological
link could not be always elucidated. This study emphasizes the
necessity of utilizing both phenotypic and genotypic methods to
characterize GRE.
 |
INTRODUCTION |
Enterococci now represent the second
leading cause of nosocomial urinary tract infections and the third
leading cause of nosocomial bacteremia (4, 22). Enterococci
can survive for prolonged periods on environmental surfaces and on the
hands of health care workers. In humans, the major reservoir of
enterococci is the gastrointestinal and genitourinary tracts (4,
22).
The genus Enterococcus includes 20 species, but most human
enterococcal infections are caused by E. faecalis
(12). E. faecium is the second most commonly
identified species (12). A few cases of infections caused by
E. durans, E. gallinarum, and
E. casseliflavus have been reported (18,
26). Identification to the species level of enterococci is not
routinely performed except for E. faecalis and
E. faecium (23), which may explain a
possible underestimation of the frequency of occurrence of the other
species.
The emergence of enterococci during the last decade has resulted mostly
from their antimicrobial resistance and less from their virulence
factors (17). The antimicrobial resistance spans different
antimicrobial groups, including
-lactam antibiotics, macrolides,
aminoglycosides, and glycopeptides. Glycopeptide-resistant enterococci (GRE), first described in 1988 (19), have been
reported in North America and several European countries (2, 5,
14-16). In certain U.S. hospitals the incidence reached
14% in 1995 (24). Three types of acquired
glycopeptide resistance are known: VanA and VanB are the most
predominant (21, 34), whereas vanD has been reported
only in one strain of E. faecium (29). VanC
glycopeptide resistance is intrinsic in E. gallinarum,
E. casseliflavus, and E. flavescens
(20, 27). The resistance is due to the synthesis of modified
peptidoglycan precursors with reduced affinity to glycopeptides
(21, 34).
The difficulty of treating infections due to GRE (10, 21),
which might be resistant to all antimicrobial agents used for treatment
of systemic infections (16, 28), emphasizes the need for
detection of acquired GRE rapidly and accurately (31, 34).
This also help to limit the intrahospital dissemination of GRE.
From August 1994 to September 1996, 28 GRE were isolated in our
laboratory. The aim of the present study was to determine the
correlation between phenotypic and genotypic identification methods, to
characterize the phenotypes and genotypes of the glycopeptide-resistant isolates, and to explore the genetic relationship between the isolates.
(This study was presented in part at the 8th European Congress of
Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland,
25 to 28 May 1997.)
 |
MATERIALS AND METHODS |
Patients and bacterial isolates.
The University Hospital of
Geneva is a 1,300-bed health care center providing primary and tertiary
care for the city and the surrounding area. GRE were isolated from
infected patients by classical microbiological techniques
(12). Whenever possible, patients infected by GRE were
subsequently screened for intestinal carriage. From stools, GRE were
isolated with selective bile-esculin-azide agar (Difco, Detroit, Mich.)
supplemented with 8 mg of vancomycin (Eli Lily) per liter
(1). A second source of GRE were stools from
immunocompromised patients hospitalized in the hematology-oncology and
bone marrow transplant units which were controlled by surveillance cultures. If a predominant organism was found, it was further analyzed
for identification. In total, 28 isolates of GRE were collected from
nineteen hospitalized patients between August 1994 and September 1996. The origins of the isolates are summarized in Table
1.
Phenotypic identification.
Identification of the isolates to
the genus level was performed by Gram staining, catalase reaction,
growth and blackening of bile-esculin agar, and growth in the presence
of 6.5% NaCl. Identification to species level was performed by using
API 20 STREP and rapid ID 32 STREP (bioMérieux, Marcy
l'Etoile, France) and the Vitek Gram Positive Identification Card
(GPI) (bioMérieux Vitek Inc., Hazelwood, Mich.), according to the
recommendations of the manufacturers. Three categories of scores for
species level identification were used: (i) excellent or very good,
(ii) good, and (iii) uncertain.
Antimicrobial susceptibility testing.
Susceptibility tests
were performed and interpreted according to guidelines from the
National Committee for Clinical Laboratory Standards (NCCLS)
(25). GRE were detected by their growth on brain heart
infusion agar (BBL Microbiology Systems, Cockeysville, Md.) containing
6 mg of vancomycin per liter, as recommended by NCCLS (25).
MICs were determined by the E-test method (AB Biodisk, Solna, Sweden)
on Mueller-Hinton agar plates (Oxoid Ltd., Basingstoke, England). The
following antibiotics were tested: penicillin, ampicillin, erythromycin, vancomycin, teicoplanin, gentamicin, and streptomycin. High-level resistance to aminoglycosides was determined by use of the
E-test with high drug concentrations (range, 0.064 to 1,024 mg/liter).
The presence of
-lactamase was determined with cefinase disks (BBL
Microbiology Systems). E. faecalis ATCC 29212 and
Staphylococcus aureus ATCC 29213 were used as quality
control strains.
Genotypic identification and determination of glycopeptide
resistance genotype.
The genes encoding
D-alanine-D-alanine ligases specific for
E. faecium (ddlE. faecium)
and for E. faecalis (ddlE.
faecalis) and the glycopeptide resistance determinants
vanA, vanB, vanC1, and
vanC2-C3 were detected by a multiplex PCR assay, as
described by Dutka-Malen et al. (9). The following
well-characterized GRE strains belonging to genotypes vanA,
vanB, and vanC were used as quality control
strains: E. faecium BM4147 (vanA),
E. faecalis V583 (vanB), E. gallinarum BM4174 (vanC1), and E. casseliflavus ATCC 25788 (vanC2).
Genotyping.
Molecular typing was performed by pulsed-field
gel electrophoresis (PFGE) with a temperature-controlled CHEF DR III
System (Bio-Rad Laboratories, Hercules, Calif.). Genomic DNA was
digested by the restriction endonuclease SmaI (New England
Biolabs, Beverly, Mass.) and additionally by EagI for
E. gallinarum. The molecular size standard (S. aureus NCTC 8325 DNA digested with SmaI) was run in
three lanes per gel. Following staining with ethidium bromide, restriction fragments were visualized by a UV transilluminator and
documented by use of a video gel documentation system (MWG-BIOTECH, Ebersberg, Germany). PFGE pattern analysis was performed with GelCompar
4.0 software (Applied Maths, Kortrijk, Belgium). The dendrograms were
calculated by the unweighted pair group method using arithmetic
averages. The restriction patterns were interpreted according to the
method of Tenover et al. (32). PFGE types were designated by
letters; subtypes (two to six band differences) were designated by
numerals.
 |
RESULTS |
GRE isolates.
From August 1994 to September 1996, a total of
28 GRE were collected from 19 patients hospitalized in various units,
including 4 isolates from the orthopedic unit, 11 isolates from the
surgical intensive care unit, 4 isolates from the hematology-oncology
unit, and nine isolates from various other units of the medical or
surgery departments (Table 1). Three patients were infected by GRE
(patients 7, 8, and 16), 5 were simultaneously infected and colonized
(patients 2, 3, 17, 18, and 19), and 11 were colonized (patients 1, 4 through 6, and 9 through 15). Three infected patients were colonized by more than one species of GRE (patients 17, 18, and 19).
Identification.
Molecular identification showed that 15 isolates were E. faecium, 4 were E. faecalis, and 8 were E. gallinarum (see Table 2).
One isolate (isolate 11) which could not be identified by the PCR
multiplex assay was identified as E. durans by API
20 STREP and as E. hirae by rapid ID 32 STREP and Vitek
GPI. The strain was considered to be E. hirae
because of its capacity to metabolize sucrose and raffinose
(13). The four isolates identified as E. faecalis by PCR were confirmed by API 20 STREP, rapid ID 32 STREP,
and Vitek GPI. Discrepancies in the species identification of
E. faecium and E. gallinarum isolates
were observed between the genotypic and phenotypic methods. Moreover,
differences in identification were observed between API 20 STREP, rapid
ID 32 STREP, and Vitek GPI. Four of the eight isolates identified as E. gallinarum by PCR assay did not ferment raffinose.
They were identified as E. faecium by API 20 STREP with
a very good identification score, and the other four isolates were
identified as E. casseliflavus (isolates 14, 15, 17, and 27). In contrast, all eight of these isolates were identified as
E. gallinarum by the rapid ID 32 STREP method, five
with an excellent score (99.9%; T = 0.85), one with a very good
score (77.3%; T = 0.56), one with a doubtful score (99.9%;
T = 0.69), and one with good identification to the genus (57.2%;
T = 0.49). The Vitek GPI method identified two isolates as
E. gallinarum (one with a good identification score and
one with a presumptive identification score), two as E. casseliflavus/gallinarum, and four as E. faecium,
one of which had a good identification score. Of the 15 isolates
identified as E. faecium by PCR, all were
identified as such by API 20 STREP and Vitek GPI, but four isolates were identified as E. gallinarum by the Rapid
ID 32 STREP assay (isolates 2, 3, 5, and 12).
Antimicrobial susceptibility testing.
Table
2 presents MICs of vancomycin for the 28 GRE isolates. Six had intermediate resistance (MIC, >4 to <32
mg/liter), and 22 were resistant (MIC
32 mg/liter). Thirteen of
these were susceptible to teicoplanin (MIC
8 mg/liter). All
E. faecalis and E. gallinarum isolates
were susceptible to penicillin (MIC
8 mg/liter) and ampicillin
(MIC
8 mg/liter). In contrast, 11 of 15 E. faecium isolates were highly resistant to penicillin (MIC
256 mg/liter) and 1 of them was resistant to ampicillin (MIC
256 mg/liter). None of the strains showed
-lactamase
activity. Only 1 isolate was highly resistant to gentamicin,
whereas 16 of 28 isolates were highly resistant to streptomycin.
Erythromycin resistance was present in 20 of 28 isolates of GRE.
One isolate of E. faecium recovered from a stool sample
(isolate 6) was highly resistant to all antimicrobial agents tested
except gentamicin.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Comparative identification and susceptibility to
antimicrobial agents of 28 GRE isolated at the University Hospital
of Geneva
|
|
Genotype of glycopeptide resistance.
The vanA gene
was detected in 18 of 28 isolates (Table 1) including 14 E. faecium, 3 E. faecalis, and 1 E. hirae. These 18 vanA isolates were all highly resistant
to vancomycin (MIC
64 mg/liter). Fifteen of these were highly
resistant to teicoplanin (MIC
64 mg/liter), whereas the other
three (isolates 10, 11, and 12) were susceptible to this compound
(MIC
4 mg/liter). The vanB gene was detected in 4 of
28 isolates, including two E. faecium isolates
(isolates 26 and 28) and two E. gallinarum isolates
(isolates 15 and 27). MICs of vancomycin for vanB strains ranged from 32 to 256 mg/liter, whereas those of teicoplanin remained in the susceptibility range (MIC
4 mg/liter). All eight
E. gallinarum isolates contained the vanC1
gene. The six isolates of E. gallinarum containing the
vanC1 gene without the additional glycopeptide resistance
gene (isolates 7 through 9, 14, 16, and 17) showed intermediate
resistance to vancomycin (MIC = 8 to 16 mg/liter) and
susceptibility to teicoplanin (MIC
2 mg/liter). When patients were colonized by different species of enterococci, similar genotypes were observed for the different species of a single patient
(vanA for patients 17 and 18 and vanB for patient
19).
Genotyping.
The results of genotyping are presented in Table 1
and Fig. 1, 2, and 3. Analysis of PFGE patterns obtained with the 15 E. faecium isolates showed a cluster of 9 isolates of
E. faecium vanA (isolates 2 through 6, 19, 20, 22, and
25) with identical or similar banding patterns (PFGE pattern B, zero to
six fragment differences) (Fig. 1). These
isolates came from five patients (patients 2 through 4, 17, and 18) who
were hospitalized in three different wards. In addition, the
E. faecium stool isolates (isolates 1 and 12) from two
other patients (patients 1 and 10) differed by only three fragments and
may be considered probably genetically related (PFGE pattern A) (Fig.
1). The two isolates of E. faecium vanB (isolates 26 and 27) from the same patient (patient 19) present differences in six
bands and were interpreted as possibly related (PFGE pattern M) (Fig.
1). The other E. faecium isolates (isolates 13 and 18),
from patients 11 and 16, were not related. The E. faecalis isolates (isolates 21, 23, and 24) from patients 17 and 18, who were hospitalized in the surgical intensive care unit in the
same time period, appeared to be identical (PFGE pattern L) (Fig.
2). Among the E. gallinarum isolates, two isolates (isolates 7 and 16) from two
different patients (5 and 14) showed identical banding patterns (PFGE
pattern C1) (Fig. 3). The six other
isolates (isolates 8, 9, 14, 15, 17, and 27), from patients 6, 7, 12, 13, 15, and 19, including the two E. gallinarum
isolates with the vanB gene, were not related (Fig. 3).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 1.
PFGE restriction fragment patterns of
SmaI-digested genomic DNA obtained from
glycopeptide-resistant E. faecium isolates and a
dendrogram showing similarities. Numbering of isolates corresponds to
the numbering in Tables 1 and 2.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
PFGE restriction fragment patterns of
SmaI-digested genomic DNA obtained from
glycopeptide-resistant E. faecalis isolates and a
dendrogram showing similarities. Numbering of isolates corresponds to
the numbering in Tables 1 and 2.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
PFGE restriction fragment patterns of
EagI-digested genomic DNA obtained from
glycopeptide-resistant E. gallinarum isolates and a
dendrogram showing similarities. Numbering of isolates corresponds to
the numbering in Tables 1 and 2.
|
|
 |
DISCUSSION |
The present study emphasizes the difficulties of phenotypical
characterization of clinical isolates of GRE. Characterizing GRE
allows the distinction between acquired GRE and intrinsic GRE to be
made. This is important for clinicians and for implementation of
infection control measures (21, 31, 34). Acquired GRE are
more difficult to treat than intrinsic GRE due to their broad-spectrum antimicrobial resistance. Moreover, only acquired resistance is transferable to other enterococci and is associated with nosocomial epidemics (21, 34). In the present study, three limitations of the phenotypic methods used for both the identification of enterococci and the determination of the type of glycopeptide resistance are highlighted. First, enterococci are not correctly identified to the species level by phenotypic methods. Second, because
intrinsic GRE can acquire additional genes of vancomycin resistance,
the identification of enterococci to the species level does not predict
the glycopeptide resistance type. Third, discrepancies between the VanA
and VanB phenotypes and their correspondent vanA and
vanB genotypes may exist.
Our results showed that three commercially available kits frequently
used in microbiology laboratories for identification of enterococci
(API 20 STREP, Rapid ID 32 STREP, and Vitek GPI), failed to
differentiate some E. gallinarum isolates from
E. faecium, or vice versa: E. gallinarum isolates that did not ferment raffinose were
misidentified as E. faecium by API 20 STREP and Vitek
GPI. Rapid ID 32 STREP, which performed well for the identification of
E. gallinarum, failed to identify some E. faecium isolates, which it misidentified as E. gallinarum. These findings, previously reported for API 20 STREP
(15) and Rapid ID 32 STREP (33), emphasize that
based on biochemical reactions, it is not possible to
differentiate between E. faecium and
E. gallinarum, which belong to the same
biochemical group, group II (12). With regard to these
results, the characterization of GRE based on phenotypic identification
(31) of enterococci cannot be recommended.
For the first time, as far as we are aware, two E. gallinarum isolates were found harboring the vanB gene.
The two strains were isolated from two different patients 6 months
apart and were not related by PFGE. Dutka-Malen et al. have
previously reported the transfer of the vanA gene to
E. gallinarum and E. casseliflavus (8). The acquisition of additional glycopeptide resistance genes by intrinsic GRE emphasizes that the characterization of intrinsic GRE should be based on genotypic analysis of the
van type. Using phenotypic methods, VanB resistance is
difficult to detect because MICs of vancomycin may be only moderately
increased, comparable to those of the VanC type (11, 21).
Of the 18 GRE with the vanA genotype analyzed in the present
study, three isolates were susceptible to teicoplanin, corresponding to
a VanB phenotype. This finding was previously reported by others (34). Conversely, it has been reported that some strains of the vanB genotype can have a VanA phenotype, with
coresistance to both vancomycin and teicoplanin (33). Thus,
for unusual isolates the phenotype cannot be inferred from the
genotype, and vice versa.
The multiplex PCR assay proposed by Dutka-Malen et al. (9)
and used in the present study presents a clear advantage over phenotypic methods with regard to specificity and rapidity.
Identification of the most frequently occurring species of enterococci
and determination of vanA and vanB genotypes were
performed in a single reaction. In conjunction with the determination
of MICs of vancomycin and teicoplanin, this approach is useful for
microbiology laboratories facing the need to characterize GRE. In
the present study only one isolate, a strain of E. hirae, could not be identified by the multiplex PCR assay, because
the primers of the D-alanine-D-alanine ligase
gene specific to this species were not included in the assay.
No epidemiological conclusion can be drawn from this study
concerning extent of colonization, because GRE were not
looked for prospectively in the stools. However, of the five infected patients analyzed for stool carriage of GRE, all were found to be
positive with a similar or related strain, confirming the role of the
gastrointestinal tract as a reservoir of GRE. In addition, three
patients were colonized by several GRE belonging to different species,
two with E. faecium and E. faecalis
containing the vanA gene and one with E. faecium and E. gallinarum containing the vanB gene. This suggests an in vivo transfer of glycopeptide
resistance in the intestinal tract, as previously reported for
the vanA determinant (8). It also emphasizes
that, with regard to the recent report of a vanB
transferable determinant in Streptococcus bovis in France (30), the dissemination of vanB resistance to
enterococcal species other than E. faecium and
E. faecalis or to other genera should be closely
monitored.
The results of the present study showed a predominance of E. faecium with the vanA gene among acquired GRE with both
sporadic cases and clusters of cases. The major cluster of five
patients included four of the five patients infected with E. faecium vanA. The dissemination of the same strain of
E. faecium vanA within a single unit may be easily
explained by cross-contamination. However, we have no explanation for
the recovery of a similar strain of E. faecium vanA
after an interval of 1 year in two different units. It emphasizes that
the mechanisms by which resistance is disseminated within hospitals
have not been fully elucidated (21) and are more complex
than initially thought. In Europe, the food chain has been suspected to
be a source of GRE (3, 21) in relation to the use of
avoparcin as a food additive for animals (21). The isolation
in the present study of an E. hirae strain supports
this hypothesis, as this species is predominant in the digestive tracts
of poultry and cattle (6, 7).
In conclusion, this study shows the importance of characterizing GRE by
both phenotypic and genotypic methods. With the rapid increase in the
occurrence of such isolates, the use of both types of methods will
provide useful information for clinicians and will implement infection
control measures.
 |
ACKNOWLEDGMENTS |
We thank P. Courvalin for providing reference strains and P. Majcherczyk and P. Moreillon for kindly reviewing the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Central
Laboratory of Bacteriology, University Hospital, 25 rue
Micheli-du-Crest, 1211 Geneva 4, Switzerland. Phone: (41) (22) 372 73 09. Fax: (41) (22) 372 73 04. E-mail:
Nadia.Liassine{at}hcuge.ch.
 |
REFERENCES |
| 1.
|
Barton, A. L., and G. V. Doern.
1995.
Selective media for detecting gastrointestinal carriage of vancomycin-resistant enterococci.
Diagn. Microbiol. Infect. Dis.
23:119-122[Medline].
|
| 2.
|
Boyce, J. M.,
S. M. Opal,
J. W. Chow,
M. J. Zervos,
G. Potter-Bynoe,
C. B. Sherman,
R. L. C. Romulo,
S. Fortna, and A. A. Medeiros.
1994.
Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance.
J. Clin. Microbiol.
32:1148-1153[Abstract/Free Full Text].
|
| 3.
|
Chadwick, P. R.,
N. Woodford,
E. B. Kaczmarski,
S. Gray,
R. A. Barrell, and B. A. Oppenheim.
1996.
Glycopeptide-resistant enterococci isolated from uncooked meat.
J. Antimicrob. Chemother.
38:908-909[Free Full Text].
|
| 4.
|
Chenoweth, C., and D. Shaberg.
1990.
The epidemiology of Enterococci.
Eur. J. Clin. Microbiol. Infect. Dis.
9:80-89[Medline].
|
| 5.
|
Clark, N. C.,
R. C. Cooksey,
B. C. Hill,
J. M. Swenson, and F. C. Tenover.
1993.
Characterization of glycopeptide-resistant enterococci from U.S. hospitals.
Antimicrob. Agents Chemother.
37:2311-2317[Abstract/Free Full Text].
|
| 6.
|
Devriese, L. A.,
J. Hommez,
R. Wijfels, and F. Haesebrouck.
1991.
Composition of the enterococcal and streptococcal intestinal flora of poultry.
J. Appl. Bacteriol.
71:46-50[Medline].
|
| 7.
|
Devriese, L. A.,
L. Laurier,
P. De Herdt, and F. Haesebrouck.
1992.
Enterococcal and streptococcal species isolated from faeces of calves, young cattle and diary cows.
J. Appl. Bacteriol.
72:29-31[Medline].
|
| 8.
|
Dutka-Malen, S.,
B. Blaimont,
G. Wauters, and P. Courvalin.
1994.
Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus.
Antimicrob. Agents Chemother.
38:1675-1677[Abstract/Free Full Text].
|
| 9.
|
Dutka-Malen, S.,
S. Evers, and P. Courvalin.
1995.
Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.
J. Clin. Microbiol.
33:24-27[Abstract].
|
| 10.
|
Eliopoulos, G. M.
1993.
Increasing problems in the therapy of enterococcal infections.
Eur. J. Clin. Microbiol. Infect. Dis.
12:409-412[Medline].
|
| 11.
|
Endtz, H. P.,
N. Van Den Braak,
A. Van Belkum,
W. H. Goessens,
D. Kreft,
A. B. Stroebel, and H. A. Verbrugh.
1998.
Comparison of eight methods to detect vancomycin resistance in enterococci.
J. Clin. Microbiol.
36:592-594[Abstract/Free Full Text].
|
| 12.
|
Facklam, R. R., and D. F. Sahm.
1995.
Enterococcus, p. 308-314.
In
P. R. Murray, E. J. Barron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
|
| 13.
|
Farrow, J. A. E., and M. D. Collins.
1985.
Enterococcus hirae, a new species that includes amino acid assay strain NCDO 1258 and strains causing growth depression in young chickens.
Int. J. Syst. Bacteriol.
35:73-75.
|
| 14.
|
Frieden, T. R.,
S. S. Munsiff, and D. E. Low.
1993.
Emergence of vancomycin-resistant enterococci in New York City.
Lancet
342:76-79[Medline].
|
| 15.
|
Gordts, B.,
H. Van Landuyt,
M. Ieven,
P. Vandame, and H. Goossens.
1995.
Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients.
J. Clin. Microbiol.
33:2842-2846[Abstract].
|
| 16.
|
Handwerger, S.,
B. Raucher,
D. Altarac,
J. Monka,
S. Marchione,
K. V. Singh,
B. E. Murray,
J. Wolff, and B. Walters.
1993.
Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.
Clin. Infect. Dis.
16:750-755[Medline].
|
| 17.
|
Jett, B. D.,
M. M. Huycke, and M. S. Gilmore.
1994.
Virulence of enterococci.
Clin. Microbiol. Rev.
7:462-478[Abstract/Free Full Text].
|
| 18.
|
Kaplan, A. H.,
P. H. Gilligan, and R. R. Facklam.
1988.
Recovery of resistant enterococci during vancomycin prophylaxis.
J. Clin. Microbiol.
26:1216-1218[Abstract/Free Full Text].
|
| 19.
|
Leclercq, R.,
E. Derlot,
J. Duval, and P. Courvalin.
1988.
Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.
N. Engl. J. Med.
319:157-161[Medline].
|
| 20.
|
Leclercq, R.,
S. Dutka-Malen,
J. Duval, and P. Courvalin.
1992.
Vancomycin resistance gene vanC is specific to Enterococcus gallinarum.
Antimicrob. Agents Chemother.
36:2005-2008[Abstract/Free Full Text].
|
| 21.
|
Leclercq, R., and P. Courvalin.
1997.
Resistance to glycopeptides in enterococci.
Clin. Infect. Dis.
24:545-556[Medline].
|
| 22.
|
Moellering, R. C.
1992.
Emergence of Enterococcus as a significant pathogen.
Clin. Infect. Dis.
14:1173-1178[Medline].
|
| 23.
|
Murray, B. E.
1990.
The life and times of the enterococcus.
Clin. Microbiol. Rev.
3:46-65[Abstract/Free Full Text].
|
| 24.
|
Murray, B. E.
1995.
What can we do about vancomycin-resistant enterococci?
Clin. Infect. Dis.
20:1134-1136[Medline].
|
| 25.
|
National Committee for Clinical Laboratory Standards.
1997.
Performance standards for antimicrobial disk susceptibility tests. Approved standard M100-S7.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 26.
|
Nauschvetz, W. F.,
S. B. Trevino,
L. S. Harrison,
R. N. Longfield,
L. Fletcher, and W. G. Wartham.
1993.
Enterococcus casseliflavus as an agent of nosocomial bloodstream infections.
Med. Microbiol. Lett.
2:102-108.
|
| 27.
|
Navarro, F., and P. Courvalin.
1994.
Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens.
Antimicrob. Agents Chemother.
38:1788-1793[Abstract/Free Full Text].
|
| 28.
|
Pegues, D. A.,
C. F. Pegues,
P. L. Hibberd,
D. S. Ford, and D. C. Hooper.
1997.
Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital.
J. Clin. Microbiol.
35:1565-1570[Abstract].
|
| 29.
|
Perichon, B.,
P. Reynolds, and P. Courvalin.
1997.
VanD-type glycopeptide-resistant Enterococcus faecium BM4339.
Antimicrob. Agents Chemother.
41:2016-2018[Abstract].
|
| 30.
|
Poyart, C.,
C. Pierre,
G. Quesne,
B. Pron,
P. Berche, and P. Trieu-Cuot.
1997.
Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis.
Antimicrob. Agents Chemother.
41:24-29[Abstract].
|
| 31.
|
Sahm, D. F.,
L. Free,
C. Smith,
M. Eveland, and L. M. Mundy.
1997.
Rapid characterization schemes for surveillance isolates of vancomycin-resistant enterococci.
J. Clin. Microbiol.
35:2026-2030[Abstract].
|
| 32.
|
Tenover, F. C.,
R. D. Arbeit,
R. V. Goering,
P. A. Mickelsen,
B. E. Murray,
D. H. Persing, and B. Swaminathan.
1995.
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.
J. Clin. Microbiol.
33:2233-2239[Medline].
|
| 33.
|
Vandamme, P.,
E. Vercauteren,
C. Lammens,
N. Pensart,
M. Ieven,
B. Pot,
R. Leclercq, and H. Goossens.
1996.
Survey of enterococcal susceptibility patterns in Belgium.
J. Clin. Microbiol.
34:2572-2576[Abstract].
|
| 34.
|
Woodford, N.,
A. P. Johnson,
D. Morrison, and D. C. E. Speller.
1995.
Current perspectives on glycopeptide resistance.
Clin. Microbiol. Rev.
8:585-615[Abstract].
|
Journal of Clinical Microbiology, July 1998, p. 1853-1858, Vol. 36, No. 7
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
van den Braak, N., Goessens, W., van Belkum, A., Verbrugh, H. A., Endtz, H. P.
(2001). Accuracy of the VITEK 2 System To Detect Glycopeptide Resistance in Enterococci. J. Clin. Microbiol.
39: 351-353
[Abstract]
[Full Text]
-
Schooneveldt, J. M., Marriott, R. K., Nimmo, G. R.
(2000). Detection of a vanB Determinant in Enterococcus gallinarum in Australia. J. Clin. Microbiol.
38: 3902-3902
[Full Text]
-
Kobayashi, K., Rao, M., Keis, S., Rainey, F. A., Smith, J. M. B., Cook, G. M.
(2000). Enterococci with reduced susceptibility to vancomycin in New Zealand. J Antimicrob Chemother
46: 405-410
[Abstract]
[Full Text]
-
BARNAUD, G., BINGEN, E.
(2000). Genotypic characterisation of endemic VanA Enterococcus faecium strains isolated in a paediatric hospital. J Med Microbiol
49: 793-799
[Abstract]
[Full Text]
-
Nelson, R. R. S., McGregor, K. F., Brown, A. R., Amyes, S. G. B., Young, H.-K.
(2000). Isolation and Characterization of Glycopeptide-Resistant Enterococci from Hospitalized Patients over a 30-Month Period. J. Clin. Microbiol.
38: 2112-2116
[Abstract]
[Full Text]